Hemodialysis access with on-off functionality

• US 7,588,551 B2
• Filed: 04/11/2007
• Issued: 09/15/2009
• Est. Priority Date: 06/20/2001
• Status: Expired due to Fees

• Current Assignee: Michael Gertner
• Original Assignee: Michael Gertner
• Inventors: Gertner, Michael
• Primary Examiner(s): Zalukaeva; Tatyana
• Assistant Examiner(s): Treyger; Ilya Y
• Application Number:
  US11/734,186
• Publication Number:
  US 20070249987A1
• Time in Patent Office: 888 Days
• Field of Search: 604/4.01, 604/16.16, 604/6.08, 604 501- 504, 604/6.16, 604/7.8, 604 19- 22, 604/27, 604/890.1, 604/891.1, 210645-647, 210/696, 210/739, 210/745, 210/746, 210/748, 210/194, 2101951-1952, 210/252, 210/257.1, 210/257.2, 210/321.6, 600437-439, 600/454, 600/458.9, 600/461.2, 600/464, 600466-470, 600/11, 600/15, 606/1, 606/8, 606/10, 606 32- 34, 606/108, 606/127, 606/128, 606/195, 606/110, 607 1- 3, 607/44, 607/60, 607/61, 607/80, 607/88, 607/90, 607/94, 607 96-101, 607104-106
• US Class Current: 604/9
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61M 1/16 with membranes
• CPC Class Codes: A61M 1/36 Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
• CPC Class Codes: A61M 1/3653 Interfaces between patient blood circulation and extra-corporal blood circuit
• CPC Class Codes: A61M 1/3655 Arterio-venous shunts or fistulae
• CPC Class Codes: A61M 1/3659 Cannulae pertaining to extracorporeal circulation
• CPC Class Codes: A61M 1/3661 for haemodialysis
• CPC Class Codes: A61M 1/3672 Means preventing coagulation
• CPC Class Codes: A61M 1/3673 Anticoagulant coating, e.g. Heparin coating

Abstract

A treatment assembly is positioned along an AV-fistula and couples therapeutic energy to an adjacent area due to a material response to an applied energy field from a remotely located energy source. The treatment assembly may be delivered into the fistula through a hemodialysis needle, or may be secured to the fistula graft itself and implanted therewith within a patient. A cover provides a shield between an anastomosis area and blood flow. Another AV-fistula includes a valved reservoir that receives a fluid agent from a hemodialysis needle while moving the needle into or from the fistula; the agent leaks from the reservoir into the fistula lumen. Another valved fistula is adjustable between an open condition and closed conditions during and between hemodialysis treatments, respectively. Another AV-fistula has a bladder reservoir coupled to a second refillable fluid reservoir and is adapted to locally deliver a therapeutic agent into the fistula lumen.

Claims

1. An arteriovenous graft system, comprising:

an arteriovenous graft having an arterial end and an opposite venous end;

at least one valve device positioned at the arterial end of said arteriovenous graft; and

a second valve device positioned at the venous end of said arteriovenous graft;

wherein said valve device comprises an inflatable balloon in communication with said arteriovenous graft;

wherein said valve device has a closed position when said inflatable balloon is inflated;

wherein when the valve device is in the closed position, arterial blood flow into the arteriovenous graft is prevented;

wherein said second valve device comprises an inflatable balloon; and

wherein said first valve device and said second valve device substantially prevent blood flow into said arteriovenous graft from either the arterial end or venous end when respective inflatable balloons are inflated.

2. A system as defined in claim 1:

wherein said inflatable balloon of said first valve device and said inflatable balloon of said second valve device each have an annular shape; and

wherein said first and second inflatable balloons are positioned inside the arteriovenous graft and expand to said closed position such that the balloons, when in the expanded condition, engage an internal wall of the arteriovenous graft.

3. A system as defined in claim 1:

wherein each of said valve devices further comprises an injection port in fluid communication with each of said inflatable balloons.

4. A subcutaneous arteriovenous graft system, comprising:

an arteriovenous graft having an arterial end and an opposite venous end;

a first valve device positioned at the arterial end of said arteriovenous graft;

wherein said first valve device comprises;

an inflatable balloon;

wherein said inflatable balloon is positioned so as to prevent blood flow into the arterial end of said arteriovenous graft when inflated;

wherein said inflatable balloon is in communication with a first injection port, and

wherein the injection port is configured to be implanted subcutaneously; and

a second valve device positioned at the venous end of said arteriovenous graft;

wherein said second valve device comprises;

an inflatable balloon;

wherein the inflatable balloon is positioned so as to prevent blood flow into the venous end of said arteriovenous graft when inflated;

wherein the inflatable balloon is in communication with a second injection port.

5. A process for reducing hyperplasia in an arteriovenous graft, comprising:

providing an arteriovenous graft having been subcutaneously implanted in a patient;

wherein said arteriovenous graft comprises;

an arterial end in fluid communication with an artery and a venous end in fluid communication with a vein; and

a first valve device positioned at the arterial end of said graft; and

closing said first valve device at the arterial end of said arteriovenous graft;

whereby blood flow into the arterial end of said arteriovenous graft is stopped;

wherein said arteriovenous graft further comprises a second valve device positioned at the venous end of said graft; and

wherein the process further comprises the step of closing said second valve device after flushing said graft.

6. A process as defined in claim 5:

wherein said first valve device and said second valve device each comprise an inflatable balloon;

wherein said inflatable balloon is positioned inside the ateriovenous graft so as to restrict blood flow through the entirety of said arteriovenous graft when inflated.

7. A process as defined in claim 6:

wherein said inflatable balloon of said first valve device and said inflatable balloon of said second valve device each have an annular shape.

8. A process for reducing hyperplasia in an arteriovenous graft, comprising:

providing an arteriovenous graft having been subcutaneously implanted in a patient;

wherein said arteriovenous graft comprises;

an arterial end in fluid communication with an artery and a venous end in fluid communication with a vein; and

a first valve device positioned at the arterial end of said graft;

closing said first valve device at the arterial end of said arteriovenous graft;

whereby blood flow into the arterial end of said arteriovenous graft is stopped; and

delivering a fluid agent inside the ateriovenous graft when the ateriovenous graft is in the closed condition.

9. A method as recited in claim 8:

wherein said fluid agent is configured to prevent clotting or hyperplasia; and

wherein said process further comprises eluting the fluid agent into the arteriovenous graft.

10. A process for reducing hyperplasia in an arteriovenous graft, comprising:

providing an arteriovenous graft having been subcutaneously implanted in a patient;

wherein said arteriovenous graft comprises;

an arterial end in fluid communication with an artery and a venous end in fluid communication with a vein; and

a first valve device positioned at the arterial end of said graft;

closing said first valve device at the arterial end of said arteriovenous graft;

whereby blood flow into the arterial end of said arteriovenous graft is stopped;

a second valve positioned at the venous end of the ateriovenous graft;

wherein said first valve device and said second valve device each comprise an inflatable balloon;

purging blood out of the venous end of the ateriovenous graft after the balloon has closed the arterial end; and

filling the second balloon to expand upon and engage an internal wall of the ateriovenous graft at the venous end to close off the ateriovenous graft.

11. A method as recited in claim 10, wherein ateriovenous graft is configured to be closed for a time period spanning the entire time between hemodialysis treatments without clotting.

12. A method as recited in claim 11, wherein said time period is at least two days.

13. An arteriovenous graft system, comprising:

an arteriovenous graft having an arterial end and an opposite venous end;

a first valve device positioned at the arterial end of said arteriovenous graft; and

a second valve device positioned at the venous end of said arteriovenous graft;

wherein the first and second valve devices have open and closed positions;

wherein when the first and second valve devices are in the closed position, arterial blood flow is prevented from flowing into the arteriovenous graft such that the graft retains a column of fluid.

14. The system of claim 13, wherein the arteriovenous graft is configured to elute a fluid agent into the column of fluid.